Background The management of gastrointestinal stromal tumors (GIST) has evolved very
rapidly in the last 4 years. The objectives of this international consensus meeting were to …

The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly …

Gastrointestinal stromal tumours (GIST) have an incidence of ~1.2 per 10 5 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …

Background Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST).
We aimed to assess dose dependency of response and progression-free survival with …

Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook
a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–…

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients with
gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop …

Highlights • This Clinical Practice Guideline provides key recommendations on the management
of soft tissue and visceral sarcomas. • Recommendations have been agreed following a …

Macrophage infiltration has been identified as an independent poor prognostic factor in
several cancer types. The major survival factor for these macrophages is macrophage colony-…

Tumor growth promotes the expansion of CD4 + CD25 + regulatory T (T reg) cells that counteract
T cell–mediated immune responses. An inverse correlation between natural killer (NK) …